GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score

Autor: Mindie H. Nguyen, Kristin C. Mara, Jianliang Dai, Benyam D. Addissie, Sravanthi Lavu, J. Paul Theobald, Nasra H. Giama, Gregory J. Gores, Jo Ann Rinaudo, Ju Dong Yang, William S. Harmsen, Hamdi A. Ali, Jorge A. Marrero, Catherine D. Moser, Fatima Hassan, K. Rajender Reddy, Loretta K. Allotey, Ziding Feng, Melissa Ward, Alex S. Befeler, Jessica L. Cvinar, Alicia Algeciras-Schimnich, Lewis R. Roberts, Nicha Wongjarupong, Denise M. Harnois, Myron Schwartz, Hawa M. Ali, Hiroyuki Yamada, Katsuyuki Miyabe, Sudhir Srivastava, Ning Zhang
Rok vydání: 2019
Předmět:
Zdroj: Cancer Epidemiology, Biomarkers & Prevention. 28:531-538
ISSN: 1538-7755
1055-9965
Popis: Background: The GALAD score is a serum biomarker–based model that predicts the probability of having hepatocellular carcinoma (HCC) in patients with chronic liver disease. We aimed to assess the performance of the GALAD score in comparison with liver ultrasound for detection of HCC. Methods: A single-center cohort of 111 HCC patients and 180 controls with cirrhosis or chronic hepatitis B and a multicenter cohort of 233 early HCC and 412 cirrhosis patients from the Early Detection Research Network (EDRN) phase II HCC Study were analyzed. Results: The area under the ROC curve (AUC) of the GALAD score for HCC detection was 0.95 [95% confidence interval (CI), 0.93–97], which was higher than the AUC of ultrasound (0.82, P Conclusions: The performance of the GALAD score was superior to ultrasound for HCC detection. The GALADUS score further enhanced the performance of the GALAD score. Impact: The GALAD score was validated in the United States.
Databáze: OpenAIRE